

=> d his

(FILE 'HOME' ENTERED AT 16:53:49 ON 28 SEP 2006)

FILE 'REGISTRY' ENTERED AT 16:53:53 ON 28 SEP 2006

L1 STRUCTURE UPLOADED

L2 733 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:54:21 ON 28 SEP 2006

L3 27 S L2 AND (STROKE OR (TRAUMA(P)BRAIN OR SPINAL))

L4 7 S L2 AND (STROKE? OR ISCHEMIA?)

L5 153 S L2 AND (BRAIN OR SPINAL CORD INJURY OR (SPINAL CORD(P)TRAUMA)

L6 8 S L2 AND (BRAIN(P) (TRAUMA OR INJURY) OR SPINAL CORD INJURY OR (

L7 8 S L2 AND (BRAIN(P) (TRAUMA OR INJURY) OR SPINAL CORD INJURY OR (

FILE 'STNGUIDE' ENTERED AT 17:00:29 ON 28 SEP 2006

FILE 'HCAPLUS' ENTERED AT 17:07:28 ON 28 SEP 2006

L8 8 S L6


L9 8 S L7

L10 3 S L2 AND TBI

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,CH2

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 16:53:49 ON 28 SEP 2006)

FILE 'REGISTRY' ENTERED AT 16:53:53 ON 28 SEP 2006

L1 STRUCTURE UPLOADED

L2 733 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:54:21 ON 28 SEP 2006

L3 27 S L2 AND (STROKE OR (TRAUMA(P)BRAIN OR SPINAL))

L4 7 S L2 AND (STROKE? OR ISCHEMIA?)

=> s l2 and (brain or spinal cord injury or (spinal cord(P)trauma))

1054 L2

528541 BRAIN

64163 SPINAL

68275 CORD

139794 INJURY

3168 SPINAL CORD INJURY

(SPINAL(W)CORD(W)INJURY)

64163 SPINAL

68275 CORD

40695 SPINAL CORD

(SPINAL(W)CORD)

16342 TRAUMA

1020 SPINAL CORD(P)TRAUMA

L5 153 L2 AND (BRAIN OR SPINAL CORD INJURY OR (SPINAL CORD(P)TRAUMA))

=> s l2 and (brain(P)(trauma or injury) or spinal cord injury or (spinal cord(P)trauma))

1054 L2

528541 BRAIN

16342 TRAUMA

139794 INJURY

18898 BRAIN(P)(TRAUMA OR INJURY)

64163 SPINAL

68275 CORD

139794 INJURY

3168 SPINAL CORD INJURY

(SPINAL(W)CORD(W)INJURY)

64163 SPINAL

68275 CORD

40695 SPINAL CORD

(SPINAL(W)CORD)

16342 TRAUMA

1020 SPINAL CORD(P)TRAUMA

L6 8 L2 AND (BRAIN(P)(TRAUMA OR INJURY) OR SPINAL CORD INJURY OR (SPINAL CORD(P)TRAUMA))

=> s l2 and (brain(P)(trauma or injury) or spinal cord injury or (spinal cord(P)trauma))

1054 L2

528541 BRAIN

16342 TRAUMA

139794 INJURY

18898 BRAIN(P)(TRAUMA OR INJURY)

64163 SPINAL

68275 CORD

139794 INJURY

3168 SPINAL CORD INJURY

(SPINAL(W)CORD(W)INJURY)

64163 SPINAL

68275 CORD

40695 SPINAL CORD

(SPINAL (W) CORD)

16342 TRAUMA

1020 SPINAL CORD (P) TRAUMA

L7

8 L2 AND (BRAIN (P) (TRAUMA OR INJURY) OR SPINAL CORD INJURY OR  
(SPINAL CORD (P) TRAUMA))

=> e KOZIKOWSKI/in

E1	5	KOZIKARO ELISHA M/IN
E2	1	KOZIKOSKI TIMOTHY E/IN
E3	0 -->	KOZIKOWSKI/IN
E4	4	KOZIKOWSKI ALAN/IN
E5	54	KOZIKOWSKI ALAN P/IN
E6	2	KOZIKOWSKI ALAN PAUL/IN
E7	1	KOZIKOWSKI ALANNA J/IN
E8	1	KOZIKOWSKI ALLAN P/IN
E9	5	KOZIKOWSKI BARBARA A/IN
E10	2	KOZIKOWSKI CARRIE L/IN
E11	1	KOZIKOWSKI CASIMIR P/IN
E12	1	KOZIKOWSKI EUGENE/IN

=> e

E13	1	KOZIKOWSKI MACIEJ/IN
E14	1	KOZIKOWSKI STAN D/IN
E15	2	KOZIKOWSKI STANISLAW D/IN
E16	1	KOZIKOWSKIP ALAN P/IN
E17	1	KOZILEK JOSEPH/IN
E18	15	KOZIMA AKIO/IN
E19	1	KOZIMA GAKU/IN
E20	2	KOZIMA HIROSHI/IN
E21	1	KOZIMA JUNPEI/IN
E22	1	KOZIMA KATSUMI/IN
E23	2	KOZIMA KATUHIRO/IN
E24	1	KOZIMA KAZUO/IN

=> s e4-e16

	4	"KOZIKOWSKI ALAN"/IN
	54	"KOZIKOWSKI ALAN P"/IN
	2	"KOZIKOWSKI ALAN PAUL"/IN
	1	"KOZIKOWSKI ALANNA J"/IN
	1	"KOZIKOWSKI ALLAN P"/IN
	5	"KOZIKOWSKI BARBARA A"/IN
	2	"KOZIKOWSKI CARRIE L"/IN
	1	"KOZIKOWSKI CASIMIR P"/IN
	1	"KOZIKOWSKI EUGENE"/IN
	1	"KOZIKOWSKI MACIEJ"/IN
	1	"KOZIKOWSKI STAN D"/IN
	2	"KOZIKOWSKI STANISLAW D"/IN
	1	"KOZIKOWSKIP ALAN P"/IN
L16	76	("KOZIKOWSKI ALAN"/IN OR "KOZIKOWSKI ALAN P"/IN OR "KOZIKOWSKI ALAN PAUL"/IN OR "KOZIKOWSKI ALANNA J"/IN OR "KOZIKOWSKI ALLAN P"/IN OR "KOZIKOWSKI BARBARA A"/IN OR "KOZIKOWSKI CARRIE L"/IN OR "KOZIKOWSKI CASIMIR P"/IN OR "KOZIKOWSKI EUGENE"/IN OR "KOZIKOWSKI MACIEJ"/IN OR "KOZIKOWSKI STAN D"/IN OR "KOZIKOWSKI STANISLAW D"/IN OR "KOZIKOWSKIP ALAN P"/IN)

=> d his

L1	STRUCTURE UPLOADED
L2	733 S L1 SSS FULL

=> s l2 and l16

	60 L2
L17	0 L2 AND L16

=> file stnguide

	Type	L #	Hits	Search Text	DBs
1	BRS	L2	4	"5958920"	USPAT
2	BRS	L3	90	KOZIKOWSKI.in.	USPAT
3	BRS	L4	7	KOZIKOWSKI.in. and (spinal.clm. or truamatic.clm. or brain.clm. or stroke.clm.)	USPAT
4	BRS	L5	0	KOZIKOWSKI.in. and diketopip\$	USPAT
5	BRS	L6	0	KOZIKOWSKI.in. and diketop\$	USPAT
6	BRS	L7	4	KOZIKOWSKI.in. and diketo\$	USPAT
7	BRS	L8	0	KOZIKOWSKI.in. and TRH	USPAT
8	BRS	L9	1	faden.in. and TRH	USPAT

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:754407 HCAPLUS

DN 141:271579

TI Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents

IN Briggs, Michael; Ornberg, Richard; Hauser, Scott; Koki, Alane

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078113	A2	20040916	WO 2004-US3219	20040205
	WO 2004078113	A3	20051013		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004204472	A1	20041014	US 2004-773019	20040205
PRAI	US 2003-451885P	P	20030304		
IT	Brain, disease (stroke; treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents)				
IT	51-57-0, Methamphetamine hydrochloride 53-43-0, Dehydroepiandrosterone 55-03-8, Synthroid 55-06-1, Tertroxin 56-85-9, L-Glutamine, biological studies 58-08-2, Caffeine, biological studies 90-84-6, Diethylpropion 111-58-0 122-09-8, Phentermine 156-08-1, Benzphetamine 299-42-3, Ephedrine 300-62-9, Amphetamine 300-62-9D, Amphetamine, compds. 364-98-7, Diazoxide 458-24-2, Fenfluramine 634-03-7, Phendimetrazine 657-24-9, Metformin 768-94-5, Amantadine 1675-54-3, Bisphenol A diglycidyl ether 2207-50-3, Aminorex 3239-44-9, Dexfenfluramine 4350-09-8, 5-Hydroxytryptophan 5411-22-3, Benzphetamine hydrochloride 5843-53-8, Asenlix 6893-02-3, Cyronine 7440-47-3D, Chromium, derivs. 9007-92-5, Glucagon, biological studies 9011-97-6, Cholecystokinin 9015-71-8, Corticotropin releasing hormone 9038-70-4, Somatomedin 14639-25-9 14838-15-4, Phenylpropanolamine 16590-41-3, Naltrexone 19036-73-8, (+)Norfenfluramine 22232-71-9, Mazindol 25332-39-2, Trazodone hydrochloride 25550-58-7, Dinitrophenol 25614-03-3 31362-50-2, Bombesin 34911-55-2, Bupropion 51481-61-9, Cimetidine 53109-32-3, Cyclohistidylproline 56296-78-7, Fluoxetine hydrochloride 59729-33-8, Citalopram 61718-82-9, Fluvoxamine maleate 71125-38-7, Meloxicam 76963-41-2, Nizatidine 79617-96-2, Sertraline 84467-54-9 86209-51-0, Beacon 96829-58-2, Orlistat 97240-79-4, Topiramate 103628-48-4, Sumatriptan succinate 106602-62-4, Amylin 106650-56-0, Sibutramine 117628-82-7, Follistatin 127121-08-8, Phytostanol 159089-37-9, Phenfen 162011-90-7, Rofecoxib 168273-06-1, Rimobant 169494-85-3D, Leptin, derivs. 169590-41-4, Deracoxib 181695-72-7, Valdecoxib 198470-84-7, Parecoxib 202409-33-4, Etoricoxib 215122-74-0 215123-80-1 220991-20-8, Lumiracoxib 245359-74-4D, Orexin, compds. 443794-06-7, Calpain 10 756819-21-3 756819-22-4 756819-23-5 756819-24-6 756819-25-7 757232-02-3, Botanical P 57 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents)				
IT	53109-32-3, Cyclohistidylproline RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

(treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents)

RN 53109-32-3 HCAPLUS

CN Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(1H-imidazol-4-ylmethyl)-, (3S,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:991513 HCAPLUS

DN 140:27828

TI Preparation of 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones as poly(ADP-ribosyl)transferase (PARP) inhibitors

IN Dullweber, Frank; Klein, Thomas; Wagner, Thomas; Weinbrenner, Steffen; Boer, Rainer

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003104233	A1	20031218	WO 2003-EP5834	20030604
	W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	AU 2003240742	A1	20031222	AU 2003-240742	20030604
PRAI	EP 2002-12704	A	20020607		
	WO 2003-EP5834	W	20030604		

OS MARPAT 140:27828

AB Title compds. I [wherein A = G1-G4; CR1R2 = carbonyl; or R1 = H and R2 = hydroxyethyl, dialkylaminocarbonyl, pyrrolidinyl, 4-fluorophenylcarbonyl, 4-methoxyphenylcarbonyl, or (un)substituted thiophenyl, furanyl, benzimidazolyl, pyrrolyl, pyrazolyl, (is)oxazolyl, (iso)thiazolyl, triazolyl, tetrazolyl, triazinyl, Ph, or PhCH2; or R1 = OH and R2 = (un)substituted alkynyl, Ph, or PhCH2; or R1 = AcO and R2 = (un)substituted Ph or PhCH2; R4 = 4-fluorophenoxyethyl or (un)substitute Ph or PhCH2; R5 = H or alkyl; R6 = H or alkyl; R7 = H, (cyclo)alkyl, pyridyl(methyl), thiophenyl(methyl), or (un)substituted alkyl, Ph, or PhCH2; or CNR6R7 = (3-hydroxy)pyrrolidinyl; R8 = alkoxycarbonyl and R9 = H; or R8 = H and R9 = OH or hydroxymethyl; and salts or N-oxides thereof] were prepared as novel active poly(ADP-ribosyl)transferase (PARP) inhibitors. For example, II was prepared starting from 2-chloro-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one (original text and data incomplete). Twenty-seven compds. of the invention suppressed human PARP-1 activity with PARP-1 inhibitory values [measured as -log IC50 (mol/l)] of about 5 or greater. Thus, I and their pharmaceutical compns. are useful for the treatment of cancer, inflammation, ischemia/reperfusion

injury during organ transplantation surgery, cerebral stroke,  
myocardial infarct, and diabetes mellitus (no data).

IT Brain, disease

(stroke, treatment; preparation of imidazo[4,5,1-ij]quinolinones  
as PARP inhibitors)

IT 634590-31-1P 634590-32-2P 634590-33-3P 634590-34-4P 634590-35-5P,  
2-(3-Hydroxymethylpiperidin-1-yl)-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-  
one 634590-36-6P, 2-(3-Hydroxypiperidin-1-yl)-4,5-dihydroimidazo[4,5,1-  
ij]quinolin-6-one 634590-37-7P 634590-38-8P 634590-39-9P  
634590-40-2P 634590-41-3P 634590-42-4P 634590-43-5P,  
2-[4-Hydroxy-4-(3-phenoxy-1-propynyl)piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-44-6P,  
2-[4-Hydroxy-4-(3-methoxy-prop-1-ynyl)piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-45-7P 634590-46-8P,  
2-[4-(Thiophen-2-yl)piperidin-1-yl]-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-  
one 634590-47-9P, 2-[4-[3-(Methoxycarbonyl)benzyl]piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-48-0P 634590-49-1P  
634590-50-4P, 2-[4-(Methoxycarbonyl)piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-51-5P,  
2-(4-Propylpiperidin-1-yl)-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one  
634590-52-6P, 2-[4-(3-Methoxyphenyl)piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-53-7P,  
2-(4-Hydroxymethylpiperidin-1-yl)-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-  
one 634590-54-8P, 2-[4-(3-Trifluoromethylphenyl)piperidin-1-yl]-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-55-9P,  
2-(4-Hydroxy-piperidin-1-yl)-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one  
634590-56-0P, 2-(4-Hydroxy-4-benzylpiperidin-1-yl)-4,5-  
dihydroimidazo[4,5,1-ij]quinolin-6-one 634590-57-1P,  
2-[4-[(tert-Butoxycarbonyl)amino]piperidin-1-yl]-4,5-dihydroimidazo[4,5,1-  
ij]quinolin-6-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(PARP inhibitor; preparation of imidazo[4,5,1-ij]quinolinones as PARP  
inhibitors)


IT 634590-49-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(PARP inhibitor; preparation of imidazo[4,5,1-ij]quinolinones as PARP  
inhibitors)

RN 634590-49-1 HCAPLUS

CN Spiro[piperidine-4,3'-(4'H)-pyrrolo[1,2-a]pyrazine]-1',4'-(2'H)-dione,  
1-(5,6-dihydro-6-oxo-4H-imidazo[4,5,1-ij]quinolin-2-yl)tetrahydro- (9CI)  
(CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:378076 HCAPLUS  
DN 137:304530



TI Multicomponent antithrombotic effect of the neuroprotector  
 prolyl-containing dipeptide GVS-111 and its metabolite  
 cyclo-L-prolylglycine  
 AU Ostrovskaya, R. U.; Lyapina, L. A.; Pastorova, V. E.; Mirzoev, T. Kh.;  
 Gudasheva, T. A.; Seredenin, S. B.; Ashmarin, I. P.  
 CS Lab. Psikhofarmakol., Inst. Farmakol., RAMN, Moscow, 125315, Russia  
 SO Eksperimental'naya i Klinicheskaya Farmakologiya (2002), 65(2), 34-37  
 CODEN: EKFAE9; ISSN: 0869-2092  
 PB Izdatel'stvo Folium  
 DT Journal  
 LA Russian  
 ST nootropic dipeptide GVS 111 metabolite antithrombotic fibrinolytic  
 stroke; fibrin platelet aggregation inhibitor antithrombotic  
 dipeptide GVS 111  
 IT Brain, disease  
 (stroke; antithrombotic action mechanism of nootropic  
 dipeptide GVS-111 and its metabolite: promising antistroke agent)  
 IT 3705-27-9, Cyclo-L-prolylglycine 157115-85-0, GVS-111  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antithrombotic action mechanism of nootropic dipeptide GVS-111 and its  
 metabolite: promising antistroke agent)  
 IT 3705-27-9, Cyclo-L-prolylglycine  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antithrombotic action mechanism of nootropic dipeptide GVS-111 and its  
 metabolite: promising antistroke agent)  
 RN 3705-27-9 HCAPLUS  
 CN Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-, (8aS)-(9CI) (CA INDEX  
 NAME)

Absolute stereochemistry. Rotation (-).



CORD(P) (TRAUM?) OR STROKE)

=> s l2 and (brain(P) (traum? or injur?) or spinal cord injury or spinal  
cord(P) (traum?) or stroke)

60 L2

101432 BRAIN

63219 TRAUM?

177962 INJUR?

15966 BRAIN(P) (TRAUM? OR INJUR?)

41689 SPINAL

113622 CORD

128968 INJURY

4114 SPINAL CORD INJURY

(SPINAL(W) CORD(W) INJURY)

41689 SPINAL

113622 CORD

20662 SPINAL CORD

(SPINAL(W) CORD)

63219 TRAUM?

5504 SPINAL CORD(P) (TRAUM?)

196073 STROKE

L13

15 L2 AND (BRAIN(P) (TRAUM? OR INJUR?) OR SPINAL CORD INJURY OR  
SPINAL CORD(P) (TRAUM?) OR STROKE)